Visit

1. Site Team Introduction and Visit Objectives

The visit begins with a meeting between the CRA, Principal Investigator (PI), and study coordinator. Objectives, timelines, and any critical issues from previous visits are reviewed.

2. Source Data Verification (SDV)

• Review of Informed Consent Forms (ICFs) for completeness and version control
• Cross-check of data entered in CRFs against source notes and hospital records
• Documentation of adverse events, concomitant medications, and visit schedules

3. IP Accountability and Storage Review

• Check receipt, dispensing, returns, and destruction logs of the investigational product
• Inspect temperature logs, expiry dating, and storage conditions (e.g., refrigerator calibration)
• Ensure segregation of used and unused stock

4. Regulatory Document Review

• Review and update of site’s Investigator Site File (ISF)
• Check for missing GCP certificates, CVs, training logs, and delegation logs
• Update protocol amendments and EC approvals
• Include templates as per Pharma SOPs and sponsor expectations

5. Protocol Deviation Tracking

• Review site deviation log
• Discuss any unreported deviations or missed visits
• Assess corrective and preventive actions (CAPA)

6. Data Query Resolution

• Address pending queries in the eCRF
• Provide justification or corrections for data discrepancies
• Ensure timely resolution and documentation in CTMS

End-of-Day Summary and Follow-Up

Once all reviews are complete, the CRA provides a verbal summary and discusses findings and next steps. A formal Monitoring Visit Report (MVR) and Follow-Up Letter are submitted within 5 working days. These documents are archived in the Trial Master File (TMF) and eTMF systems like Veeva Vault.

Checklist for Site Staff Before CRA Visit

1. ☐ Update Delegation Log and Training Records
2. ☐ Prepare Informed Consent Forms (ICFs) in chronological order
3. ☐ Print all outstanding queries from eCRF
4. ☐ Confirm IP storage and accountability documentation
5. ☐ Ensure lab reports and visit notes are filed
6. ☐ Prepare responses to previous visit findings

Best Practices for Site Staff

• Assign a point-of-contact for the visit to avoid delays
• Keep an RMV preparation checklist on-site
• Maintain a log of open queries and deviations for real-time updates
• Participate in review sessions to clarify protocol implementation

Regulatory Expectations During Monitoring

Authorities such as EMA and Stability Studies reference guidelines require that monitoring visits are adequately documented and deviations are addressed with follow-up actions. CRAs must record all findings and ensure that corrective measures are implemented before the next visit.

Common Findings in Routine Monitoring Visits

• Missing ICF pages or unapproved versions used
• Gaps in IP accountability or incomplete dispensing logs
• Delayed adverse event reporting or missing lab results
• Unreported protocol deviations
• Untrained or unlisted staff performing trial procedures

Conclusion

Routine Monitoring Visits serve as a cornerstone for maintaining the quality, safety, and integrity of clinical trials. Whether you’re a site staff member, CRA, or sponsor representative, understanding what to expect and how to prepare can significantly enhance the efficiency and compliance of your site operations. With proper preparation, adherence to GMP compliance standards, and proactive follow-up, RMVs become a powerful tool for ensuring trial success and regulatory readiness.